secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2026-05-28T12:18:14+00:00
Accession:  0001999480-26-000016
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience appoints Andrew Miller to board; former Karuna Therapeutics president
--------------------------------------------------------------------------------

- Andrew Miller, Ph.D., appointed to board effective May 27, 2026, filling vacancy after board size increased to seven.
- Miller founded Karuna Therapeutics and served as President of R&D until its acquisition by Bristol Myers Squibb in March 2024.
- Appointed to the Nominating and Corporate Governance Committee, replacing Christopher Nixon Cox.
- Initial option grant for up to 48,200 shares (Black-Scholes value ≤$400k); annual retainer $40k plus $5k for NCGC service.
- Board determined Miller is independent under NYSE and SEC rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948026000016/0001999480-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948026000016/alto-20260527.htm
  HTML page:      https://secwatch.observer/filing/0001999480-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer